Published in Neth Heart J on February 01, 2016
Evaluation of bifurcation stenting techniques at Catharina Hospital, Eindhoven in 2013. Neth Heart J (2016) 1.99
Unwarranted variation of coronary stent choice in The Netherlands. Neth Heart J (2016) 0.83
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Economic evaluation of sirolimus-eluting stents. CMAJ (2005) 1.32
Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess (2004) 1.18
Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess (2007) 1.10
Determinants of variations in coronary revascularization practices. CMAJ (2011) 1.08
Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med (2009) 1.07
Ultra-thin strut cobalt chromium bare metal stent usage in a complex real-world setting. (SOLSTICE registry). Neth Heart J (2015) 0.99
Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth Heart J (2015) 0.98
Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol (2005) 0.92
Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scand Cardiovasc J (2006) 0.90
Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. Clin Res Cardiol (2013) 0.88
Economic evaluation of drug-eluting stents: a systematic literature review and model-based cost-utility analysis. Int J Technol Assess Health Care (2007) 0.88
Variations in the use of an innovative technology by payer: the case of drug-eluting stents. Med Care (2012) 0.88
Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data. Value Health (2011) 0.87
Cost effectiveness of drug-eluting stents in Belgian practice: healthcare payer perspective. Pharmacoeconomics (2009) 0.86
Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. Int J Technol Assess Health Care (2009) 0.86
Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. J Public Health (Oxf) (2008) 0.83
Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. EuroIntervention (2010) 0.82
Economic analysis of the use of drug-eluting stents from the perspective of Belgian health care. Acta Cardiol (2007) 0.81
Stent platforms anno 2015: is there still a place for bare metal stents at the front line? Neth Heart J (2015) 0.79